Table of Contents
Trump’s move to push cannabis toward Schedule III is shaping up to be the biggest shift in federal marijuana policy in decades, even though cannabis is still, for now, officially classified in Schedule I. The new executive order signals that Washington is finally serious about overhauling how medical access, taxation, and the marijuana–hemp divide are handled at the federal level.
A new push toward Schedule III
Trump’s executive order, “Increasing Medical Marijuana and Cannabidiol Research,” tells the Attorney General and federal health agencies to stop treating rescheduling as a slow, back‑burner review and instead move it to the front of the line. It leans on years of prior analysis from health and law‑enforcement agencies but adds something those processes lacked: a clear directive from the White House to get the rescheduling process done.
None of that changes the fact that, on paper, marijuana remains a Schedule I substance until the formal rulemaking is complete and effective dates kick in. For now, the industry is operating in a kind of limbo, reading the tea leaves from Washington while still living under the old rules.
Jasmine Johnson, CEO of GŪD Essence, calls the moment a long‑overdue correction: “Federal rescheduling marks a long‑overdue shift toward treating cannabis as the medical, economic, and community issue it truly is—not a criminal one.”
Research, medical access, and patients
One of the most immediate impacts of the order is on research. By telling agencies to expand work on medical marijuana and cannabidiol, the administration is trying to loosen constraints that have made serious cannabis research slow, expensive, and hard to scale. More registered growers, more approved studies, and clearer pathways for clinical trials could finally let universities, hospitals, and life‑science companies catch up with what patients and consumers have been doing for years.
That shift matters for patients because it is the path to standardized dosing, reliable product categories, and evidence‑backed indications instead of a patchwork of anecdotes and stigma. Johnson sums it up simply: “For patients, rescheduling means better access, more consistent standards, and products backed by research instead of stigma.” She also notes that when operators are not punished for playing by the rules, they can put more money into “jobs, education, and community infrastructure” instead of defensive legal and tax structures.
Money, taxes, and industry shakeup
If marijuana does land in Schedule III, the single biggest near‑term change for licensed operators will be the end of Internal Revenue Code 280E for those businesses. Right now, 280E blocks standard deductions for things like payroll, rent, and marketing, leaving many cannabis companies with punishing effective tax rates that would be unthinkable in most other industries.
Removing 280E for compliant operators would free up a meaningful amount of capital across the industry, allowing businesses to hire, expand, and invest instead of watching cash get eaten by taxes. A clearer federal posture and better margins are also likely to draw more bank financing and institutional money into the space, which could fuel mergers, acquisitions, and consolidation—good news for some, but a real pressure point for smaller or under‑resourced operators.
At the same time, Schedule III status will bring cannabis closer to other medically recognized controlled substances, which means more scrutiny of manufacturing standards, testing, recordkeeping, and marketing claims. Johnson warns that “rescheduling alone is not the finish line—but it is a critical foundation,” and she argues that policy makers must make sure “small, minority‑owned, and legacy‑rooted businesses are not left behind as the industry evolves,” rather than letting only the largest players capture the upside.
Hemp, cannabinoids, and cleaning up the mess
The rescheduling push is also forcing a broader conversation about hemp and the wider cannabinoid market, which has existed in a legal gray area since the 2018 Farm Bill. Hemp‑derived cannabinoids—including intoxicating products like delta‑8 THC sold outside licensed dispensaries—have flourished in a patchwork of inconsistent state rules and spotty enforcement.
As marijuana moves toward recognized medical status at the federal level, it becomes harder to justify radically different treatment for functionally similar cannabinoid products just because one comes from “hemp” and the other from “marijuana.” Over time, that is likely to push regulators toward a more coherent, risk‑ and potency‑based approach that looks at what a product does, not just where it came from, with big implications for product strategy across both hemp and cannabis.
The road ahead: what really matters now
Right now, the Controlled Substances Act still lists marijuana in Schedule I, and the rescheduling rule is not yet final, so this period is best understood as a transition rather than a victory lap. What happens next will decide whether this ends up being a narrow technical change or a true reset of how the United States handles cannabis.
- Finishing the rulemaking and setting priorities: DEA still has to complete notice‑and‑comment rulemaking, deal with public input and potential lawsuits, and spell out how Schedule III marijuana will be handled for registration, recordkeeping, and treaty compliance. DOJ and federal prosecutors will then set enforcement priorities, which will matter a lot for unlicensed operators and the remaining illicit market.
- Rebuilding tax and finance around a post‑280E world: Once 280E no longer applies to licensed operators, business models, valuations, and deal structures will shift quickly. Companies that built elaborate structures just to cope with 280E may unwind them and redirect that energy into growth, compliance, and product development instead.
- Clarifying FDA and product rules: Recognizing medical use at Schedule III will increase pressure on FDA to say more about how it views cannabinoid medicines, supplements, and consumer products. Over time, that likely means stronger expectations around evidence, manufacturing quality, and labeling, which will help serious operators but could squeeze out lower‑quality or non‑compliant products.
- Making equity and justice part of the shift: Rescheduling by itself does not clear records or erase criminal penalties; many federal offenses and collateral consequences stay on the books unless Congress or states choose to act. Advocates are already pushing to link rescheduling with expungement, resentencing, and targeted support for legacy and minority‑owned operators so the communities hit hardest by prohibition are not shut out of the regulated market.
- Bringing hemp and grey markets into a coherent system: Policymakers also have to decide what to do with the existing hemp and intoxicating‑cannabinoid markets, which will not simply vanish when marijuana moves to Schedule III. A more coherent, potency‑driven framework could help bring those products under clearer rules instead of letting them remain in the shadows.
How these choices play out will determine whether Schedule III is just a line change in federal law or the starting point for a safer, fairer, and more economically stable cannabis and hemp ecosystem. Used well, this transition is a chance to align tax policy, research, product standards, and equity—turning a technical rescheduling into the backbone of a more durable cannabis economy.
